Bullish Case: HUN is flat at $8.14 but the term structure flipped to contango with Helium term-IV lower-bound ~15.6 near-term vs the prior hump, and Q3 earnings (early Nov) already fully priced at 44-48 IV — a non-catastrophic print plus any purchase/FTC or call flow continuation (69% more volume than puts; the Nov 10C traded with delta 0.1 despite only 10-12 contracts) could squeeze, while the Helium price-uncertainty chart shows mass at $8-9 upside recovery territory.

Bearish Case: The return distribution is centred on flat to slightly negative; HUN remains -74.5% over 5 years and -50% decade, chemicals demand/M&A tail risks are unresolved, and Nov 8P delta -0.41 IV 45.9 alongside Jan 8P IV 50.8 shows the surface still pays a meaningful premium for downside hedges — a negative earnings print would likely re-rate lower toward $7.

Potential Outcomes:

1. Range $7.50-$9.00 into Jan earnings — 40%: Helium & market PDFs both peak at $8, contango, no momentum.
2. Grind lower to $6.50-$7.50 on weak demand/chem overcapacity — 25%: return-surface long-run likelihood skews modest negative; falsifiable if deep-put IV compresses.
3. Upside pop to $9.50-$11 on positive earnings or deal tail — 20%: falsifiable if price-up + IV-down + contango steepens further.
4. Vol spike / macro risk-off to $5.50-$6.50 — 10%: falsifiable if SPY IV surfaces turn red-hot alongside HUN.
5. Breakout >$11 on M&A call flow — 5%: falsifiable if deep call-wing IV compresses while spot rises.

October 10, 2026